MarketCapExport financials
XBiotech (XBIT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
XBiotech Balance Sheet 2025-2011 | XBIT
Brief balance sheet overview of XBiotech
The review uses the five latest available annual reports between 2021 and 2025.
Assets finished at $150.1 million versus $275.2 million initially, losing -45.5%. The balance sheet contracted.
Asset growth of -45.5% came with a +68% rise in liabilities. Financial leverage became more prominent.
Equity accounts for 93.5% of assets. Against the initial 97.9%, the capital position looks resilient.
The cash reserve occupies 83.7% of the balance sheet, previously 86.1%. It is one marker of short-term resilience.
The balance sheet carries negative retained earnings of -$136.4 million. The figure may result from accumulated losses or an active capital return policy.
Balance sheet takeaway
XBiotech 's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.
Annual Balance Sheet XBiotech
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | - | -237 M | -715 M | -15.8 M | -31.8 M | -34.3 M | -91.1 M | -57.3 M | -7.24 M | -4.17 M | - |
Total Non Current Liabilities |
- | - | - | - | - | 1.12 M | 1.06 M | 3 K | 18 K | 23 K | 17 K | - | - | 30 K | - |
Total Current Liabilities |
7.93 M | 15.1 M | 6.1 M | 4.07 M | 3.45 M | 3.98 M | 60.2 M | 2.94 M | 2.79 M | 7.96 M | 6.29 M | 3.15 M | - | - | - |
Total Liabilities |
9.73 M | 16.8 M | 7.77 M | 5.7 M | 5.79 M | 5.1 M | 61.2 M | 2.95 M | 2.81 M | 7.99 M | 6.31 M | 3.15 M | 845 K | 1.1 M | - |
Deferred Revenue |
- | - | - | - | - | - | 4.5 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-136 M | -90.8 M | -52.3 M | -27.7 M | 5.15 M | 97.6 M | 431 M | -238 M | -217 M | -183 M | -131 M | -93.2 M | -71.4 M | -61.5 M | - |
Total Assets |
150 M | 199 M | 227 M | 246 M | 275 M | 354 M | 817 M | 44.3 M | 63 M | 67 M | 109 M | 62.2 M | 11.1 M | 8.47 M | - |
Cash and Cash Equivalents |
126 M | 173 M | 200 M | 157 M | 237 M | 237 M | 715 M | 15.8 M | 31.8 M | 34.3 M | 91.1 M | 57.3 M | 7.24 M | 4.17 M | - |
Book Value |
140 M | 182 M | 219 M | 240 M | 269 M | 349 M | 756 M | 41.4 M | 60.2 M | 59.1 M | 103 M | 59 M | 10.2 M | 7.37 M | - |
Total Shareholders Equity |
140 M | 182 M | 219 M | 240 M | 269 M | 349 M | 756 M | 41.4 M | 60.2 M | 59.1 M | 103 M | 59 M | 10.2 M | 7.37 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet XBiotech
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Liabilities |
9.73 M | 4.82 M | 16.8 M | 5.34 M | 5.62 M | 7.15 M | 16.8 M | 17.7 M | 18.9 M | - | 7.77 M | 6.94 M | 6.07 M | 5.22 M | 5.7 M | 6.02 M | 10.7 M | 5.24 M | 5.79 M | 5.36 M | 5.39 M | 3.84 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 2.95 M | 2.95 M | 2.95 M | 2.95 M | 2.81 M | 2.81 M | 2.81 M | 2.81 M | 7.99 M | 7.99 M | 7.99 M | 7.99 M | 6.31 M | 6.31 M | 6.31 M | 6.31 M | 3.15 M | 3.15 M | 3.15 M | 3.15 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.5 M | 4.5 M | 4.5 M | 4.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-136 M | -142 M | -90.8 M | -109 M | -103 M | -102 M | -90.8 M | -80.3 M | -75.3 M | - | -52.3 M | -47.7 M | -40.3 M | -31.6 M | -27.7 M | -24.5 M | -11.9 M | -244 K | 5.15 M | 11.6 M | 89.9 M | 95 M | 97.6 M | 97.6 M | 97.6 M | 97.6 M | 431 M | 431 M | 431 M | 431 M | -238 M | -238 M | -238 M | -238 M | -217 M | -217 M | -217 M | -217 M | -183 M | -183 M | -183 M | -183 M | -131 M | -131 M | -131 M | -131 M | -93.2 M | -93.2 M | -93.2 M | -93.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
150 M | 140 M | 199 M | 172 M | 179 M | 182 M | 199 M | 210 M | 216 M | - | 227 M | 230 M | 235 M | 242 M | 246 M | 251 M | 266 M | 271 M | 275 M | 280 M | 354 M | 356 M | 354 M | 354 M | 354 M | 354 M | 817 M | 817 M | 817 M | 817 M | 44.3 M | 44.3 M | 44.3 M | 44.3 M | 63 M | 63 M | 63 M | 63 M | 67 M | 67 M | 67 M | 67 M | 109 M | 109 M | 109 M | 109 M | 62.2 M | 62.2 M | 62.2 M | 62.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
126 M | 115 M | 173 M | 147 M | 153 M | 156 M | 173 M | 183 M | 189 M | - | 200 M | 202 M | 143 M | 152 M | 157 M | 161 M | 226 M | 232 M | 237 M | 239 M | 315 M | 240 M | 237 M | 237 M | 237 M | 237 M | 715 M | 715 M | 715 M | 715 M | 15.8 M | 15.8 M | 15.8 M | 15.8 M | 31.8 M | 31.8 M | 31.8 M | 31.8 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 91.1 M | 91.1 M | 91.1 M | 91.1 M | 57.3 M | 57.3 M | 57.3 M | 57.3 M | 7.24 M | - | - | - | 4.17 M | - | - | - | - | - | - | - |
Book Value |
140 M | 135 M | 182 M | 167 M | 173 M | 175 M | 182 M | 192 M | 197 M | - | 219 M | 223 M | 229 M | 237 M | 240 M | 245 M | 256 M | 266 M | 269 M | 274 M | 349 M | 352 M | 349 M | 349 M | 349 M | 349 M | 756 M | 756 M | 756 M | 756 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 60.2 M | 60.2 M | 60.2 M | 60.2 M | 59.1 M | 59.1 M | 59.1 M | 59.1 M | 103 M | 103 M | 103 M | 103 M | 59 M | 59 M | 59 M | 59 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
182 M | 135 M | 219 M | 167 M | 173 M | 175 M | 182 M | 192 M | 197 M | 209 M | 219 M | 223 M | 229 M | 237 M | 240 M | 245 M | 256 M | 266 M | 269 M | 274 M | 349 M | 352 M | 349 M | 349 M | 349 M | 349 M | 756 M | 756 M | 756 M | 756 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 60.2 M | 60.2 M | 60.2 M | 60.2 M | 59.1 M | 59.1 M | 59.1 M | 59.1 M | 103 M | 103 M | 103 M | 103 M | 59 M | 59 M | 59 M | 59 M | 10.2 M | - | - | - | 7.37 M | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of XBiotech , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Kura Oncology
KURA
|
$ 9.88 | -1.0 % | $ 866 M |  USA |
 |
Arvinas
ARVN
|
$ 7.56 | -1.37 % | $ 536 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.62 | -2.41 % | $ 431 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
$ 67.74 | 0.28 % | $ 13 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
$ 38.31 | -1.01 % | $ 2.2 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
$ 8.18 | 3.81 % | $ 125 M |  Australia |
 |
CNS Pharmaceuticals
CNSP
|
$ 4.83 | -3.31 % | $ 2.14 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | USA |
 |
MacroGenics
MGNX
|
$ 3.59 | 2.87 % | $ 227 M | USA |
 |
iBio
IBIO
|
$ 0.84 | 2.31 % | $ 87.4 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
$ 62.86 | -1.7 % | $ 7.55 M | USA |
 |
Immunome
IMNM
|
$ 18.0 | 0.45 % | $ 1.57 B | USA |
 |
Immuron Limited
IMRN
|
$ 0.97 | -4.9 % | $ 224 M | Australia |
 |
Moderna
MRNA
|
$ 245.81 | 1.54 % | $ 95.6 B | USA |
 |
InMed Pharmaceuticals
INM
|
$ 1.36 | 1.49 % | $ 5.66 M |  Canada |
 |
INmune Bio
INMB
|
$ 1.61 | 0.62 % | $ 39.9 M | USA |
 |
Novo Nordisk A/S
NVO
|
$ 39.06 | -0.71 % | $ 174 B |  Danmark |
 |
Inovio Pharmaceuticals
INO
|
$ 0.8 | -21.26 % | $ 37.5 M | USA |
 |
Insmed Incorporated
INSM
|
$ 94.04 | -1.7 % | $ 18.7 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.75 | -0.51 % | $ 760 M | USA |
 |
Biogen
BIIB
|
$ 240.98 | -0.87 % | $ 35.3 B | USA |
 |
BioVie
BIVI
|
$ 1.26 | 1.61 % | $ 1.86 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
$ 44.27 | -2.49 % | $ 7.08 B | USA |
 |
Innate Pharma S.A.
IPHA
|
$ 1.57 | -0.51 % | $ 141 M |  France |
 |
NextCure
NXTC
|
$ 5.42 | -0.46 % | $ 15.4 M | USA |
 |
BeyondSpring
BYSI
|
$ 0.5 | -5.13 % | $ 20.6 M | USA |
 |
Capricor Therapeutics
CAPR
|
$ 5.88 | -11.04 % | $ 273 M | USA |
 |
Vaxcyte
PCVX
|
$ 63.23 | -4.53 % | $ 8.6 B | USA |
 |
Oncolytics Biotech
ONCY
|
$ 0.51 | 2.57 % | $ 48.9 M | Canada |
 |
Outlook Therapeutics
OTLK
|
$ 0.56 | 7.94 % | $ 19.5 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
$ 3.37 | -1.46 % | $ 568 M |  Singapore |
 |
Passage Bio
PASG
|
$ 3.59 | -0.28 % | $ 11.5 M | USA |
|
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
$ 83.44 | -1.92 % | $ 4.19 B | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 1.66 | -2.92 % | $ 163 M | USA |
|
Immatics N.V.
IMTX
|
$ 7.69 | 2.4 % | $ 941 M |  Germany |
 |
Immunic
IMUX
|
$ 7.48 | 0.94 % | $ 1.16 B | USA |
 |
Immunovant
IMVT
|
$ 28.38 | -0.73 % | $ 5.18 B | USA |
 |
MediciNova
MNOV
|
$ 1.41 | 3.68 % | $ 69.2 M | USA |
 |
Iovance Biotherapeutics
IOVA
|
$ 14.62 | -1.62 % | $ 5.22 M | USA |
|
Rezolute
RZLT
|
$ 3.7 | -1.22 % | $ 384 M | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Canada |
 |
Krystal Biotech
KRYS
|
$ 322.17 | -1.0 % | $ 9.32 B | USA |
 |
Nektar Therapeutics
NKTR
|
$ 38.27 | -2.42 % | $ 646 M | USA |
 |
NanoViricides
NNVC
|
$ 1.51 | 0.67 % | $ 30.5 M | USA |
 |
Grifols, S.A.
GRFS
|
$ 7.5 | -0.53 % | $ 5.1 B |  Spain |
 |
Tarsus Pharmaceuticals
TARS
|
$ 70.5 | -0.75 % | $ 2.95 B | USA |
 |
Nurix Therapeutics
NRIX
|
$ 26.02 | -0.31 % | $ 2.26 B | USA |
 |
Savara
SVRA
|
$ 4.67 | -1.89 % | $ 1.04 B | USA |
 |
Ocugen
OCGN
|
$ 0.82 | 0.32 % | $ 256 M | USA |